Abstract
BACKGROUND: The relationship between systemic immune inflammation index (SII) and the prognosis of cancer has always been a subject of intense interest. However, the prognostic value of SII in non-small cell lung cancer (NSCLC) patients remains a controversial topic. OBJECTIVE: To evaluate the effect of SII index on prognosis of NSCLC. METHODS: We conducted a comprehensive search of PubMed, EMBASE, and the Cochrane Library databases to determine correlation between SII index, clinicopathological features, overall survival (OS), and progression-free survival (PFS). Odds ratio (ORs) and 95% confidence interval (CIs) were used to assess the connection between SII and clinicopathological parameters, and HRs and 95% CIs were used to assess the connection between SII and survival. RESULTS: Seventeen studies with 8,877 cases were included in the analysis. Compared with NSCLC patients with low SII level, patients with NSCLC with high SII level had a poor OS (HR = 1.75, 95% CI, 1.50-2.00; P < 0.001) and had a poor PFS (HR = 1.61, 95% CI, 1.25-1.96; P < 0.001). In addition, patients with higher pathological stage (II-III) had higher SII levels (OR = 2.32, 95% CI, 2.06-2.62; P < 0.001). CONCLUSIONS: The SII index is a promising prognostic biomarker for NSCLC and may help clinicians choose appropriate NSCLC treatments.